Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04693754
Other study ID # 2006385412
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date July 1, 2020
Est. completion date December 31, 2030

Study information

Verified date January 2024
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of having this database is to collect data related to endoscopic ultrasound RFA procedures performed by Indiana University EUS physicians for the treatment of tumors or adenopathy. This database is a repository database only, all information will be obtained in the electronic medical record. No additional clinical procedures will be performed outside current standard of care for endoscopic ultrasound. The patient will have already signed an informed consent for the endoscopic ultrasound. Subjects will be entered into the database for up to 10 years after the most recent procedure.


Description:

Radiofrequency ablation (RFA) is a well-established therapeutic option for ablation of dysplastic and neoplastic tissue by the use of local thermal coagulative necrosis. Options for administration include percutaneous or a surgical approach. Percutaneous RFA is effective and safe, but it is unfeasible in cases of lesions with interposition of organs and/or vessels. For lesions such as the pancreas, surgery-assisted RFA has been described but requires general anesthesia and is associated with a substantial risk of thermal injuries to major vessels or adjacent structures. EUS-guided RFA is a minimally invasive approach that offers high-quality real-time imaging guidance during selective ablation of benign (1-5) or malignant (6-7) pancreatic lesions. Treatment in small case series has shown to produce local necrosis with minimal adverse events. Other sites treated include the liver and metastatic adenopathy. This database will collect data related to endoscopic ultrasound RFA procedures performed by Indiana University EUS physicians for the treatment of tumors or adenopathy. No additional clinical procedures will be performed outside current standard of care for endoscopic ultrasound. The patient's information collected will be pre-procedure identification of the adenopathy, labs, the endoscopic ultrasound(s) and post procedure follow up and care related to the adenopathy. Patients will be contacted by phone at post-procedure 1 & 2 weeks and asked to report symptoms related to the procedure.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 100
Est. completion date December 31, 2030
Est. primary completion date December 31, 2030
Accepts healthy volunteers No
Gender All
Age group 14 Years and older
Eligibility Inclusion Criteria: Subjects 14 years of age and older Referral for the treatment of a benign or malignant tumor or adenopathy Exclusion Criteria: - Subjects less than 14 years of age Unable to comprehend the study consent due to language or disability

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Indiana University Health University Hospital Indianapolis Indiana

Sponsors (1)

Lead Sponsor Collaborator
Indiana University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of any procedural complications that occur during the procedure on date of procedure. This data will be used for to determine the clinical impact and safety of these procedures. Day of procedure
Primary Rate of patient report of symptoms related to procedure (Acute pancreatitis, abdominal pain, infection/abscess, venous thrombosis, & fever) 1 week phone follow up 1 week following procedure
Primary Rate of patient report of symptoms related to procedure (Acute pancreatitis, abdominal pain, infection/abscess, venous thrombosis, & fever) 2 week phone follow up 2 weeks following procedure
See also
  Status Clinical Trial Phase
Completed NCT01354795 - Prospective Study Comparing Methods of Obtainment of Specimen After EUS-FNA in Patients With Peri-pancreatic Mass N/A
Completed NCT00958841 - Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Phase 2
Terminated NCT00249301 - A Study of MLN8054 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06122896 - Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals Early Phase 1
Terminated NCT02602067 - 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients Phase 1
Recruiting NCT06411795 - Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy Phase 2
Completed NCT03622229 - EUS-FNB for Solid Pancreatic Lesions: Side-fenestrated Vs Fork-tip Needle N/A
Recruiting NCT06400472 - A Study of LY4170156 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT02791503 - CROSSFIRE Trial: Comparing the Efficacy of Irreversible Electroporation With Radiotherapy N/A
Recruiting NCT05786716 - DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations Phase 2/Phase 3
Completed NCT05745415 - Cancer Stem Cell Specific Aptamer's Ability to Detect Blood Circulating Cancer Stem Cells and Its Role as a Predictor of Prognosis in Pancreatic Cancer
Completed NCT03322592 - EUS-FNB With ROSE Vs. EUS-FNB Without ROSE N/A
Recruiting NCT05083247 - Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma Phase 2
Completed NCT00436423 - A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer Phase 2
Completed NCT02900950 - Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary Cancer N/A
Completed NCT00711191 - A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas Phase 1
Completed NCT00222898 - Cancer Detection in Pancreatic Cysts N/A
Completed NCT00034281 - Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 Phase 1
Completed NCT00005926 - Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas Phase 2
Recruiting NCT04164017 - Impact of Suction in the EUS-guided Fine Needle Biopsy of Solid Pancreatic Lesions N/A